Terminal complement inhibition dampens the inflammation during COVID-19.
作者信息
Kulasekararaj Austin G, Lazana Ioanna, Large Joanna, Posadas Kristina, Eagleton Helen, Lord Villajin John, Zuckerman Mark, Gandhi Shreyans, Marsh Judith C W
机构信息
Department of Haematological Medicine, King's College Hospital-NHS Foundation Trust, London, UK.
NIHR/Wellcome King's Clinical Research Facility, London, UK.
出版信息
Br J Haematol. 2020 Aug;190(3):e141-e143. doi: 10.1111/bjh.16916. Epub 2020 Jun 28.
Abstract
摘要
相似文献
1
Terminal complement inhibition dampens the inflammation during COVID-19.终末补体抑制可减轻新冠病毒感染期间的炎症反应。
Br J Haematol. 2020 Aug;190(3):e141-e143. doi: 10.1111/bjh.16916. Epub 2020 Jun 28.
2
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.补体 C3 与 C5 抑制在重症 COVID-19 中的作用：早期临床发现揭示了不同的生物学疗效。
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
3
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.
4
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.在三例重症新型冠状病毒肺炎患者中使用依库珠单抗进行抗补体C5治疗。
Clin Immunol. 2020 Oct;219:108555. doi: 10.1016/j.clim.2020.108555. Epub 2020 Aug 6.
5
Complement as a target in COVID-19?补体作为 COVID-19 的靶点？
Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.
6
Rationale for targeting complement in COVID-19.针对 COVID-19 靶向补体的理由。
EMBO Mol Med. 2020 Aug 7;12(8):e12642. doi: 10.15252/emmm.202012642. Epub 2020 Jul 12.
7
Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.改善慢性贫血的肾脏预后：从阵发性夜间血红蛋白尿中汲取经验。
Am J Hematol. 2010 Aug;85(8):551-2. doi: 10.1002/ajh.21800.
8
COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.接受抗补体治疗的患者感染新型冠状病毒肺炎：利兹国家阵发性夜间血红蛋白尿症服务经验
Br J Haematol. 2020 Oct;191(1):e1-e4. doi: 10.1111/bjh.17097. Epub 2020 Sep 18.
9
Silencing of immune activation with methotrexate in patients with COVID-19.使用甲氨蝶呤使新冠肺炎患者的免疫激活沉默。
J Neurol Sci. 2020 Aug 15;415:116942. doi: 10.1016/j.jns.2020.116942. Epub 2020 May 25.
10
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.2019冠状病毒病治疗的紧急途径：针对下游炎症以预防灾难性综合征。
Joint Bone Spine. 2020 May;87(3):191-193. doi: 10.1016/j.jbspin.2020.03.011.
引用本文的文献
1
Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate.脓毒症期间接触、凝血和补体系统的病理生理动力学：甲磺酸萘莫司他的潜在靶点。
J Intensive Med. 2024 Apr 10;4(4):453-467. doi: 10.1016/j.jointm.2024.02.003. eCollection 2024 Oct.
2
COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.COVID-19 疫苗接种可预防更严重的病情，在奥密克戎大流行期间，补体抑制剂治疗可减少 PNH 患者的溶血恶化：一项单中心研究。
Ann Med. 2023;55(2):2274510. doi: 10.1080/07853890.2023.2274510. Epub 2024 Jan 1.
3
Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron.中国 PNH 患者感染 SARS-CoV-2 奥密克戎后严重溶血加重。
Immun Inflamm Dis. 2023 Aug;11(8):e966. doi: 10.1002/iid3.966.
4
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.呼吸道病毒感染对阵发性睡眠性血红蛋白尿症患者突破性溶血的影响。
Int J Mol Sci. 2023 May 27;24(11):9358. doi: 10.3390/ijms24119358.
5
COVID-19 in Patients with Hematologic Diseases.血液系统疾病患者中的新型冠状病毒肺炎
Biomedicines. 2022 Nov 29;10(12):3069. doi: 10.3390/biomedicines10123069.
6
Reconstructed Genome-Scale Metabolic Model Characterizes Adaptive Metabolic Flux Changes in Peripheral Blood Mononuclear Cells in Severe COVID-19 Patients.重建的基因组规模代谢模型描绘了严重 COVID-19 患者外周血单核细胞中的适应性代谢通量变化。
Int J Mol Sci. 2022 Oct 17;23(20):12400. doi: 10.3390/ijms232012400.
7
Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.补体介导的微血管损伤和血栓形成在重症 COVID-19 发病机制中的作用：综述
World J Exp Med. 2022 Jul 20;12(4):53-67. doi: 10.5493/wjem.v12.i4.53.
8
Pancytopenia in a Case of Aplastic Anaemia/Paroxysmal Nocturnal Haemoglobinuria Unmasked by SARS-CoV-2 Infection: A Case Report.SARS-CoV-2 感染导致再生障碍性贫血/阵发性睡眠性血红蛋白尿症患者全血细胞减少症：病例报告。
Medicina (Kaunas). 2022 Sep 15;58(9):1282. doi: 10.3390/medicina58091282.
9
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.在 COVID-19 住院患者中评估研究性补体 C5 抑制剂zilucoplan 的疗效和安全性：一项开放标签随机对照试验。
Respir Res. 2022 Aug 9;23(1):202. doi: 10.1186/s12931-022-02126-2.
10
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.入院时的补体水平反映2019冠状病毒病（COVID-19）进展为重症急性肾损伤（AKI）：一项多中心前瞻性队列研究
Front Med (Lausanne). 2022 Apr 29;9:796109. doi: 10.3389/fmed.2022.796109. eCollection 2022.
本文引用的文献
1
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.COVID-19 患者的依库珠单抗治疗：来自 ASL Napoli 2 Nord 真实经验的初步结果。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047. doi: 10.26355/eurrev_202004_20875.
2
Complement as a target in COVID-19?补体作为 COVID-19 的靶点？
Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
5
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.瑞维鲁单抗（ALXN1210）对比依库珠单抗在有 C5 抑制剂治疗史的成人 PNH 患者中的疗效：302 研究。
Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3.
6
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.补体激活参与严重急性呼吸综合征冠状病毒发病机制。
mBio. 2018 Oct 9;9(5):e01753-18. doi: 10.1128/mBio.01753-18.
7
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV.阻断 C5a-C5aR 轴可减轻 hDPP4 转基因感染 MERS-CoV 的小鼠肺部损伤。
Emerg Microbes Infect. 2018 Apr 24;7(1):77. doi: 10.1038/s41426-018-0063-8.
8
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.依库珠单抗对阵发性夜间血红蛋白尿患者溶血及输血需求的影响。
N Engl J Med. 2004 Feb 5;350(6):552-9. doi: 10.1056/NEJMoa031688.
9
Natural history of paroxysmal nocturnal hemoglobinuria.阵发性夜间血红蛋白尿的自然病史。
N Engl J Med. 1995 Nov 9;333(19):1253-8. doi: 10.1056/NEJM199511093331904.
Zotero 插件